EMA guideline: no way...: [Design Issues]

posted by mittyri – Russia, 2019-12-07 21:58 (1150 d 10:30 ago) – Posting: # 20959
Views: 5,371

Dear Osama,

❝ I also agree about this as a previous acadmic person, but as a regulator, which regulatory supportive Guidelines (EMA & FDA) reasons, can I rely on it to be able to use data from study subjects who didn't completed all study periods?


I doubt that something exists at the moment.
Please also see the related discussion and cites of EMA guideline.

Kind regards,
Mittyri

Complete thread:

UA Flag
Activity
 Admin contact
22,477 posts in 4,708 threads, 1,603 registered users;
18 visitors (0 registered, 18 guests [including 3 identified bots]).
Forum time: 08:29 CET (Europe/Vienna)

The mediocre teacher tells.
The good teacher explains.
The superior teacher demonstrates.
The great teacher inspires.    William Arthur Ward

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5